Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ClearPath

Financiado

Cerrado

Amyloid-β clearance in Alzheimer's disease: Unravelling the role of endocytic pa...

Amyloid-β clearance in Alzheimer's disease: Unravelling the role of endocytic pathways of endothelial cells Alzheimer’s disease (AD) is an age-associated, irreversible neurodegenerative disorder. Α fundamental neuropathological hallmark of this disease is the accumulation of the amyloid-beta (Aβ) peptide in the extracellular space and i... ver más

30/04/2025

FOUNDATION FOR RES...

169K€

Presupuesto del proyecto: 169K€

Líder del proyecto

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-29

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

FOUNDATION FOR RESEARCH AND...

169.33K€ | Lider

IURC

N.D. | Participante

Johnd Hopkins School of Medi...

N.D. | Participante

Proyectos interesantes

ADPROGRES

Medical Technol...

Applied Physics

75K€ Cerrado

BFU2009-07341

Medical Technol...

Applied Physics

69K€ Cerrado

MAMBA

Medical Technol...

Applied Physics

2M€ Cerrado

SAF2010-15676

Medical Technol...

Applied Physics

145K€ Cerrado

FJCI-2016-28177

Medical Technol...

Applied Physics

50K€ Cerrado

SAF2010-18837

Medical Technol...

Applied Physics

133K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2023-03-29
Fecha Fin: 2025-04-30

Líder del proyecto

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 169K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Alzheimer’s disease (AD) is an age-associated, irreversible neurodegenerative disorder. Α fundamental neuropathological hallmark of this disease is the accumulation of the amyloid-beta (Aβ) peptide in the extracellular space and its aggregation in the brain. Interestingly, critical role for a healthy brain is played by clearance mechanisms of endothelial cells, which traverse the Αβ peptide through the Blood Brain Barrier (BBB), a highly selective semipermeable border. Studies in recent years have shown that endothelial cells remove Aβ by endocytosis, and that impairment of this function is key to AD progression. However, the exact contribution of the distinct individual endocytic routes, as well as the involved molecular mechanisms, are largely unexplored. Hence, the main objective of ClearPath is to undertake a holistic approach that will shed light into the unexplored endocytic routes involved in brain Aβ clearance and to identify the relationship between endocytic abnormalities and clinical pathologies of AD. To this end, ClearPath aims to: a. develop an in vitro co-culture BBB model system using endothelial and neuronal cells derived from established isogenic hiPSCs; b. screen the distinct endocytic routes to identify their contribution in Aβ clearance; c. undertake bioinformatic analysis of genome-wide datasets from AD patients, to reveal novel disease-associated genes implicated in the endocytic routes; d. use transgenic animal models to validate the role of endocytic pathways in Αβ clearance. The multidisciplinary nature of this project warrants accomplishment of the research objectives, as well as advancement of the research capacity of the Post-doctoral fellow, thus boosting her career in the field. Besides, the results of the study will improve our understanding in Aβ clearance mechanisms, thus contributing to novel strategies aiming to reduce the load of Aβ peptide in the brain, thereby preventing or delaying the onset of the disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores